title: Evaluation of an integrated in vitro-in silico PBPK (physiologically based pharmacokinetic) model to provide estimates of human bioavailability.
abstract: PK express module is a physiologically based model of first pass metabolism, which integrates in vitro data with an in silico physiologically based pharmacokinetic (PBPK) model to predict human bioavailability (F(H)). There are three required inputs: FDp (Fraction dose absorbed, final parameter from iDEA absorption module), protein binding (fu) and disappearance kinetics in human hepatocytes. Caco-2 permeability, aqueous solubility (at multiple pH's), estimated dose and chemical structure are inputs required for the estimation of FDp (Norris et al., 2000; Stoner et al., 2004) and were determined for all compounds in our laboratory or obtained from literature. Protein binding data was collected from literature references and/or Pfizer database. Human hepatocyte data was generated in-house using an automated human hepatocyte method (using Tecan Genesis Workstation) as described previously (). Sixteen compounds (commercial and Pfizer compounds) were chosen to evaluate the PK express model and the bioavailability predicted from the module was compared with known clinical endpoints. For majority of the 16 compounds (approximately 80%), the PK express model F(H) values were comparable to the known human bioavailability (F(H)) (within 23.7 units of the known human (true) F, except for PF 3, PF 4, PF 6). In conclusion, the PK express model integrates a number of key readily available discovery parameters and provides estimates of human performance by integrating in silico and experimental variables built on a physiological based pharmacokinetic model. Information from this model in conjunction with other ADME data (e.g., P450 inhibition) will enable progression of most promising compounds for further in vivo PK and/or efficacy studies.
authors.affiliation: Discovery-ADME Technology, Ann Arbor, MI 48105, USA. hongliang.cai@pfizer.com
authors.forename: Hongliang
authors.initials: H
authors.lastname: Cai
authors.forename: Chad
authors.initials: C
authors.lastname: Stoner
authors.forename: Anita
authors.initials: A
authors.lastname: Reddy
authors.forename: Sascha
authors.initials: S
authors.lastname: Freiwald
authors.forename: Danielle
authors.initials: D
authors.lastname: Smith
authors.forename: Roger
authors.initials: R
authors.lastname: Winters
authors.forename: Charles
authors.initials: C
authors.lastname: Stankovic
authors.forename: Narayanan
authors.initials: N
authors.lastname: Surendran
mesh_terms: D001682:Biological Availability; D018938:Caco-2 Cells; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D022781:Hepatocytes / Q000378:metabolism; D006801:Humans; D006863:Hydrogen-Ion Concentration; D066298:In Vitro Techniques; D007408:Intestinal Absorption; D007413:Intestinal Mucosa / Q000378:metabolism; D008954:Models, Biological; D004364:Pharmaceutical Preparations / Q000737:chemistry / Q000378:metabolism*; D010599:Pharmacokinetics; D011485:Protein Binding; D015203:Reproducibility of Results; D012189:Retrospective Studies; D012995:Solubility
chemical_list: D004364:Pharmaceutical Preparations